Sharma Sanjay, Dominguez Ana Lucia, Hoelzinger Dominique B, Lustgarten Joseph
Cancer Center Scottsdale, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA.
Cancer Immunol Immunother. 2008 Apr;57(4):549-61. doi: 10.1007/s00262-007-0393-1. Epub 2007 Sep 8.
There is accumulative evidence indicating that targeting antigen presenting cells (APCs) with different types of adjuvants could result in the induction of antitumor immune responses. It has been hypothesized that APCs function may be altered in the elderly contributing to a decline in the immune function. We evaluated whether targeting APCs following injection with Poly I:C, LPS, flagellin, imiquimod and CpG-ODN would induce an antitumor response in the old.
The immune and antitumor responses induce Poly I:C, LPS, flagellin, imiquimod and CpG-ODN were compared in young (2 month old) and old (18 months) mice.
Our results indicated that only intratumoral (i.t.) injections of CpG-ODN completely rejected the tumor in both young and old mice. Injections of Poly I:C also induced the rejection of tumors in the young but not in the old. Furthermore, i.t. injections of CpG-ODN promoted the development of protective memory responses in the young and the old. Analysis of the immune responses in the old indicated that CpG-ODN but not Poly-I:C induces: a pro-inflammatory Th1 type response; accumulation and activation of CD4+, CD8+ T and, NK cell responses; activation of APCs; and reduction in the number of Tregs. The activation of these immune-parameters positively correlates with the induction of an antitumor response.
These studies indicate that there are differences in the level of stimulation with TLR-ligands between young and old APCs and that the aged immune responses can be rescued and exploited for the induction of tumor immunity by targeting APCs with specific TLR-ligands. These results have important clinical implications for developing immunization strategies containing TLR-ligands that will be effective in both the young and old.
有越来越多的证据表明,用不同类型的佐剂靶向抗原呈递细胞(APC)可诱导抗肿瘤免疫反应。据推测,老年人的APC功能可能发生改变,导致免疫功能下降。我们评估了注射聚肌胞苷酸(Poly I:C)、脂多糖(LPS)、鞭毛蛋白、咪喹莫特和CpG寡脱氧核苷酸(CpG-ODN)后靶向APC是否会在老年小鼠中诱导抗肿瘤反应。
比较了年轻(2个月大)和年老(18个月大)小鼠中由聚肌胞苷酸、脂多糖、鞭毛蛋白、咪喹莫特和CpG-ODN诱导的免疫和抗肿瘤反应。
我们的结果表明,仅肿瘤内(i.t.)注射CpG-ODN能使年轻和年老小鼠的肿瘤完全消退。注射聚肌胞苷酸也能在年轻小鼠中诱导肿瘤消退,但在老年小鼠中则不能。此外,肿瘤内注射CpG-ODN可促进年轻和年老小鼠中保护性记忆反应的发展。对老年小鼠免疫反应的分析表明,CpG-ODN而非聚肌胞苷酸可诱导:促炎性Th1型反应;CD4+、CD8+T细胞和自然杀伤(NK)细胞反应的积累和激活;APC的激活;以及调节性T细胞(Tregs)数量的减少。这些免疫参数的激活与抗肿瘤反应的诱导呈正相关。
这些研究表明,年轻和年老的APC对Toll样受体(TLR)配体的刺激水平存在差异,并且通过用特定的TLR配体靶向APC,可以挽救和利用衰老的免疫反应来诱导肿瘤免疫。这些结果对于制定包含TLR配体的免疫策略具有重要的临床意义,该策略在年轻人和老年人中均有效。